---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-013565"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:20:30.982854+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine FY2025 net loss $201.1M; WD/AATD IND filings on track, CGD BLA planned

## Summary
- Net loss $201.1M for FY2025, cash $191.4M providing runway into 2027.
- On track to file IND/CTA for Wilson Disease (1H 2026) and AATD (mid-2026); initial clinical data expected 2027.
- Engaging FDA for PM359 in CGD; plans BLA based on Phase 1/2 data published in NEJM, targeting accelerated approval.
- Workforce reduction and deprioritization of CGD program to focus on in vivo liver franchise.
- CF program preclinical proof-of-concept data expected 2026; BMS CAR-T collaboration continues.

## SEC filing metadata
- accession: 0001628280-26-013565
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828026013565/0001628280-26-013565-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828026013565/prme-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-013565
- JSON: https://secwatch.observer/filing/0001628280-26-013565.json
- Plain text: https://secwatch.observer/filing/0001628280-26-013565.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.